Gilead Sciences, Inc.

Cv Therapeutics, Inc.

Gilead Palo Alto, Inc.

The Endowment for Research in Human Biology, Inc.

Xiaofen Li

Elfatih O Elzein

Jeff A Zablocki

Rao V Kalla

Thao Perry

Dmitry Koltun

Britton Kenneth Corkey

Robert H Jiang

Chandrasekar Venkataramani

Eric Q Parkhill

Juan A Guerrero

Tetsuya Kobayashi

Prabha N Ibrahim

Dengming Xiao

Venkata Poornapragnacharyulu Palle

Michael Graupe

Ruben Martinez

Vaibhav Varkhedkar

Gregory Notte

William John Watkins

Lan Jiang

Scott E Lazerwith

Michael L Mitchell

Hong Yang

Darryl Kato

Devan Naduthambi

Jonathan William Medley

Neil H Squires

Mark J Bartlett

David W Lin

Vickie H Tsui

Hang Chu

John Edward Knox, Jr

Anna E Hurtley

Tae H Hwang

Zachary Newby

Jennifer Leigh Cosman

Kristyna M Elbel

Tim Marquart

Kevin D Shenk

Matthew Abelman

Christopher F Morrison

Scott Preston Simonovich

Christopher Allen Ziebenhaus

Michael Organ

Elfaith O Elzein

Wing Ming Keung

Yaroslav Bilokin

Ivan Diamond

Guoxin Tao

Lina Yao

Peidong Fan

Maria Pia Arolfo

Zhan Jiang

Venkata D-011 Oakwood Estates Palle

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

MCL-1 inhibitors

Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: 

Therapeutic heterocyclic compounds

Compounds having the following Formula (I), or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, and methods of their use and preparation are disclosed: 

Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed: 

The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R, R, R, R, R, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as CaM kinase inhibitors

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W, W, W, R, Q, X, Xand Xare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Growing community of inventors

Mountain View, CA, United States of America

Xiaofen Li